--- title: "Medifast | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 75.1 M" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276173254.md" datetime: "2026-02-17T21:46:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276173254.md) - [en](https://longbridge.com/en/news/276173254.md) - [zh-HK](https://longbridge.com/zh-HK/news/276173254.md) --- > 支持的语言: [English](https://longbridge.com/en/news/276173254.md) | [繁體中文](https://longbridge.com/zh-HK/news/276173254.md) # Medifast | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 75.1 M Revenue: As of FY2025 Q4, the actual value is USD 75.1 M, beating the estimate of USD 71.4 M. EPS: As of FY2025 Q4, the actual value is USD -1.65, missing the estimate of USD -0.82. EBIT: As of FY2025 Q4, the actual value is USD -9.223 M. ### Fourth Quarter 2025 Financial and Operational Metrics - **Revenue**: Medifast, Inc. (快验保) reported revenue of $75.1 million, a decrease of 36.9% compared to $119.0 million in the fourth quarter of 2024. - **Active Earning Coaches**: The total number of active earning coaches decreased by 40.6% to 16,100, down from 27,100 in the fourth quarter of 2024. - **Revenue per Active Earning Coach**: The average revenue per active earning coach increased by 6.2% to $4,664, compared to $4,391 in the fourth quarter of 2024. - **Net Loss**: Net loss was -$18.1 million, which includes a $12.1 million non-cash valuation allowance on deferred tax balance, compared to a net income of $0.8 million in the fourth quarter of 2024. - **Gross Profit**: Gross profit decreased by 40.9% to $52.1 million from $88.2 million in the fourth quarter of 2024, with gross profit as a percentage of revenue at 69.4% compared to 74.1% in the prior-year period. - **Selling, General, and Administrative Expenses (SG&A)**: SG&A decreased by 31.5% to $59.9 million from $87.5 million in the fourth quarter of 2024, but increased as a percentage of revenue to 79.8% from 73.5%. - **Loss from Operations**: Loss from operations was -$7.8 million, or -10.4% as a percentage of revenue, compared to income from operations of $0.7 million, or 0.6% as a percentage of revenue, in the fourth quarter of 2024. - **Other Income**: Other income increased by 151.1% to $1.4 million from $0.6 million in the fourth quarter of 2024. - **Effective Tax Rate**: The effective tax rate was -183.9% for the fourth quarter of 2025, primarily due to establishing a $12.1 million non-cash valuation allowance, compared to 37.3% in the prior-year period. ### Full Year 2025 Financial Metrics - **Revenue**: For the full year 2025, revenue decreased by 36.0% to $385.8 million compared to $602.5 million in 2024. - **Net Loss**: Net loss was -$18.7 million, including a $12.1 million non-cash valuation allowance, compared to a net income of $2.1 million in 2024. - **Cash, Cash Equivalents, and Investment Securities**: As of December 31, 2025, Medifast, Inc. (快验保) had $167.3 million in cash, cash equivalents, and investment securities, compared to $162.3 million in cash and cash equivalents at December 31, 2024, with no interest-bearing debt. - **Working Capital**: Working capital was $158.7 million as of December 31, 2025, compared to $150.2 million at December 31, 2024. - **Gross Profit**: Gross profit was $275.187 million for the full year 2025, compared to $444.623 million in 2024. - **Selling, General, and Administrative Expenses (SG&A)**: SG&A was $289.400 million for the full year 2025, compared to $441.745 million in 2024. - **Loss from Operations**: Loss from operations was -$14.213 million for the full year 2025, compared to income from operations of $2.878 million in 2024. - **Other Income**: Other income was $8.574 million for the full year 2025, compared to $0.909 million in 2024. - **Provision for Income Taxes**: Provision for income taxes was $13.033 million for the full year 2025, compared to $1.696 million in 2024. ### Outlook Medifast, Inc. (快验保) expects first quarter 2026 revenue to be in the range of $65 million to $80 million, with a projected loss per share ranging from -$0.15 to -$0.70. For the full year 2026, the company anticipates revenue between $270 million and $300 million and a loss per share ranging from -$1.55 to -$2.75. ### 相关股票 - [Medifast (MED.US)](https://longbridge.com/zh-CN/quote/MED.US.md) ## 相关资讯与研究 - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-CN/news/281530653.md) - [Digital China Proposes HKD 0.036 Final Dividend for 2025 Financial Year](https://longbridge.com/zh-CN/news/281057910.md) - [Research Alert: CFRA Maintains Hold Opinion On Shares Of Commercial Metals Company](https://longbridge.com/zh-CN/news/281020997.md) - [SpaceX's $75 Billion IPO Draws Investor Focus](https://longbridge.com/zh-CN/news/281231695.md) - [Inky Updates Bylaws Following Recent Fiscal Year Change](https://longbridge.com/zh-CN/news/281297268.md)